Identification of TMB, CD8 T‐cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit–toxicity ratio of anti‐PD‐1/PD‐L1 therapy

Documents similaires

• PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
  par: Naoya Maekawa, et autres
  Publié: (2021)
• Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
  par: Hyun Tae Lee, et autres
  Publié: (2017)
• Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
  par: Zhitao Li, et autres
  Publié: (2021)
• Targeting PD-1/PD-L1 in lung cancer: current perspectives
  par: González-Cao M, et autres
  Publié: (2015)
• PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin
  par: Xiao Miao, et autres
  Publié: (2018)